Trial Profile
A double-blind, placebo-controlled, parallel group multicenter study to assess the safety, tolerance and efficacy of a single subcutaneous dose of tezampanel in patients with acute migraine.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2009
Price :
$35
*
At a glance
- Drugs Tezampanel (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors Raptor Pharmaceutical Corp
- 30 Jun 2008 Primary endpoint met, according to interim results presented at the 50th Annual Scientific Meeting of the American Headache Society, as reported in a TorreyPines media release (9090616).
- 13 May 2008 Results will be presented at the 2008 AHS Scientific Meeting, according to a TorreyPines media release.
- 22 Oct 2007 Status changed from in progress to completed.